Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
SARS-CoV-2
A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis.
Year introduced: 2021(2020)
SARS-CoV-2 variants [Supplementary Concept]
Sequence variants of SARS-COV-2 virus when compared to the reference sequence (NC_045512.2). Many are under investigation for various mutations and their potential impact on COVID-19 (e.g, transmissibility, diagnosis, vaccine effectiveness or clinical presentation or severity). For instance variant B.1.1.7 is characterized by a set of mutations including N501Y on the spike protein which binds human ACE2 PROTEIN. There are more than 900 registered variants as of February 2021.
Date introduced: December 21, 2020
COVID-19 Serological Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence antibodies specific to SARS-COV-2 or its antigens.
Year introduced: 2021
Baiya SARS-CoV-2 VAX COVID-19 vaccine [Supplementary Concept]
plant (Nicotiana benthamiana) produced SARS-CoV-2 receptor binding domain protein subunit vaccine
Date introduced: May 25, 2022
3C-like proteinase, SARS-CoV-2 [Supplementary Concept]
Date introduced: November 19, 2024
nucleocapsid phosphoprotein, SARS-CoV-2 [Supplementary Concept]
RefSeq NC_045512
Date introduced: October 1, 2020
COVID-19 Vaccines
Vaccines or candidate vaccines containing SARS-CoV-2 component antigens, genetic materials, or inactivated SARS-CoV-2 virus, and designed to prevent COVID-19.
SARS-CoV-2 recombinant spike protein with delta inulin and CpG-ODN adjuvant vaccine [Supplementary Concept]
Date introduced: August 13, 2021
papain-like protease, SARS-CoV-2 [Supplementary Concept]
spike protein, SARS-CoV-2 [Supplementary Concept]
Date introduced: March 19, 2020
COVID-19 Testing
Diagnosis of COVID-19 by assaying bodily fluids or tissues for the presence of COVID-19 antibodies, SARS-COV-2 antigens or the VIRAL RNA of SARS-COV-2.
COVID-19
A viral disorder generally characterized by high FEVER; COUGH; DYSPNEA; CHILLS; PERSISTENT TREMOR; MUSCLE PAIN; HEADACHE; SORE THROAT; a new loss of taste and/or smell (see AGEUSIA and ANOSMIA) and other symptoms of a VIRAL PNEUMONIA. A coronavirus, SARS-CoV-2 VIRUS, in the genus BETACORONAVIRUS is the causative agent.
COVID-19 Serotherapy
Transfer of blood plasma derived from patients who have recovered from COVID-19 to non-immune hosts.
Year introduced: 2023 (2020)
NS13 protein, SARS-CoV-2 [Supplementary Concept]
GenBank QHD43415
Date introduced: June 2, 2022
NSP12 protein, SARS-CoV-2 [Supplementary Concept]
NS8 protein, SARS-CoV-2 [Supplementary Concept]
GenBank QHD43422
Date introduced: June 25, 2020
nidoviral uridylate-specific endoribonuclease [Supplementary Concept]
Date introduced: March 24, 2020
SARS-CoV-2-IN-1 [Supplementary Concept]
Date introduced: December 14, 2022
vaksin merah putih - UA SARS-CoV-2 COVID-19 vaccine [Supplementary Concept]
Date introduced: August 23, 2022
WIBP COVID-19 vaccine [Supplementary Concept]
whole virus inactivated SARS-CoV-2 vaccine produced using Vero cells. Do not confused with BIBP COVID-19 vaccine
Date introduced: July 6, 2022